09R
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The compan… Read more
Market Cap & Net Worth: 09R (09R)
09R (F:09R) has a market capitalization of $20.90 Million (€20.36 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #27392 globally and #2985 in its home market, demonstrating a 3.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 09R's stock price €0.64 by its total outstanding shares 32057461 (32.06 Million).
09R Market Cap History: 2026 to 2026
09R's market capitalization history from 2026 to 2026. Data shows growth from $20.90 Million to $20.90 Million (0.00% CAGR).
09R Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 09R's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 09R by Market Capitalization
Companies near 09R in the global market cap rankings as of March 19, 2026.
Key companies related to 09R by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
09R Historical Marketcap From 2026 to 2026
Between 2026 and today, 09R's market cap moved from $20.90 Million to $ 20.90 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €20.90 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of 09R was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.90 Million USD |
| MoneyControl | $20.90 Million USD |
| MarketWatch | $20.90 Million USD |
| marketcap.company | $20.90 Million USD |
| Reuters | $20.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.